Ranitidinum hydrochloridum

75-150-300 mg Tablets. Readily available Recent EU registration dossier

Offer available for: licensing

Pharmaceutical form and dosage: 75-150-300 mg Tablets

Type:

- Generics
- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)

Therapeutic target:

- Gastrointestinal

Action: Ant-ulcerants - H2 antagonists (Gastro)

Full Description:
Ranitidinum hydrochloridum 75-150-300 mg Tablets dossier:
-New readily available for licensing
-Marketing Authorization obtained in The Netherlands and to be obtained soon Belgium (we can also register in other countries)
-Stability: 25°C: 36 months, 40°C: 6 months

Availability and Market information:

Status: Registered (MA obtained)

Market(s) and Registration Info: (date: concerns Marketing Authorization)
- Netherlands : 2000
- Belgium : 2001
Registration info: Obtained in The Netherlands, on-going in Belgium
On request: registration in other countries

Market information

Other Market Info:

Patent Information:
Name: Zantac
Patent info: Expired